Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions
Status:
Completed
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
The objective of this proposal is to test the feasibility of red blood cell (RBC)
rejuvenation to chronic transfusion in sickle cell disease (SCD) and the potential benefit of
RBC rejuvenation in this population to determine if a larger clinical trial powered to
definitively characterize the benefits of rejuvenation is warranted.
This is a small pilot study is to see if restoring important energy molecules (ATP and
2,3,DPG) in stored red blood cells before they are transfused, with a rejuvenating solution
(Rejuvesol), offers any advantages to individuals over standard blood transfusion. Subjects
will receive either rejuvenated (R) or standard (S) RBCs with each transfusion for 6
transfusions (over approximately a 6-month period) in a pre-defined order to maximize
detection of any signal.